हिंदी में पढ़ें

Pfizer

Pfizer Q2 net up 6% at Rs 158 crore

Pfizer Q2 net up 6% at Rs 158 crore

Mon, Oct 28, 2024

Total income increased to Rs 632 crore for the September quarter as against Rs 611 crore in the year-ago period, Pfizer Ltd said in a regulatory filing.

Navratna SIP by Anil Singhvi: This pharma stock can give 82% return - Check targets | Stock to BUY for Long Term

Navratna SIP by Anil Singhvi: This pharma stock can give 82% return - Check targets | Stock to BUY for Long Term

Fri, Oct 04, 2024

Navratna SIP By Anil Singhvi, Stock To Buy For Long Term: The stock market has been quite volatile and Sensex dropped 354.67 points to 82,142.43 in early trade and Nifty declined 114.1 points to 25,136.

Birthday Special : Stock of the day - Anil Singhvi recommends buying Pfizer & Vodafone Idea

Birthday Special : Stock of the day - Anil Singhvi recommends buying Pfizer & Vodafone Idea

Mon, Jun 03, 2024

Birthday Special; Stock of the day - Today Anil Singhvi gave buying advice in Pfizer & Vodafone Idea. What is stoploss and targets? See in this video.

TRENDING NOW

Pfizer shares sink after it resets 2024 COVID expectations

Pfizer shares sink after it resets 2024 COVID expectations

Thu, Dec 14, 2023

Pfizer used some of its COVID windfall to acquire companies, including a $43 billion deal for cancer drugmaker Seagen it expects to close this week, and began selling a new RSV vaccine.

Pfizer Q2 Results: Drug maker's profit declines 52% to Rs 149 crore

Pfizer Q2 Results: Drug maker's profit declines 52% to Rs 149 crore

Sat, Oct 28, 2023

Pfizer Q2 Results: Drug firm Pfizer Ltd reported 52.11 per cent decline in net profit at Rs 148.96 crore for the second quarter ended September 2023.

Pfizer June quarter numbers tumble and COVID-19 vaccine, treatment sales dry up

Pfizer June quarter numbers tumble and COVID-19 vaccine, treatment sales dry up

Wed, Aug 02, 2023

Pfizer June quarter results: Crumbling COVID-19 vaccine and treatment sales chopped Pfizer's second-quarter earnings, but both the drugmaker and Wall Street expect a rebound in the back half of 2023.

Brokerages recommend THESE three stocks for highest return in 3 months – Check the target price

Brokerages recommend THESE three stocks for highest return in 3 months – Check the target price

Fri, Dec 02, 2022

Domestic brokerage firms recommend three stocks that can yield up to 16% returns in 3 months

Glenmark Pharma inks settlement pact with Pfizer for cancer drug

Glenmark Pharma inks settlement pact with Pfizer for cancer drug

Tue, Nov 22, 2022

Shares of of the drug maker were trading 1.54 per cent up at Rs 417.9 apiece on BSE.

Q1 results FY2023: Nykaa, Petronet LNG, Garware Technical Fibres, Pfizer announce June quarter results - highlights

Q1 results FY2023: Nykaa, Petronet LNG, Garware Technical Fibres, Pfizer announce June quarter results - highlights

Fri, Aug 05, 2022

Nykaa Q1 results FY2023: FSN E-commerce, which operates under Nykaa brand, on Friday said its consolidated net profit rose nearly 42 per cent to Rs 5 crore in the April-June quarter of FY23

Pfizer, BHEL, RBL Bank most visible mid-cap companies; these 7 firms too made the cut in Top 10—Details

Pfizer, BHEL, RBL Bank most visible mid-cap companies; these 7 firms too made the cut in Top 10—Details

Thu, Apr 28, 2022

As per Wizikey, a media intelligence company that leverages AI to provide a single solution for the communications team to make data-driven decisions, Pfizer Limited, Bharat Heavy Electricals Limited (BHEL), and RBL Bank Limited have emerged as the most visible Mid-cap companies in Q1 2022

ICICI Securities upgrades Pfizer Ltd, Westlife Development ratings post q3 results; sees up to 17% upside

ICICI Securities upgrades Pfizer Ltd, Westlife Development ratings post q3 results; sees up to 17% upside

Fri, Feb 04, 2022

ICICI Securities has upgraded ratings of Pfizer ltd and Westlife Development and post strong q3fy22 results of the companies in the quarter ended December 31, 2021.

Is the COVID-19 vaccine safe for children? What FDA suggests?

Is the COVID-19 vaccine safe for children? What FDA suggests?

Thu, Dec 23, 2021

Is the COVID-19 vaccine safe for children? Yes, US regulators authorised Pfizer's vaccine for younger children after millions of 12-to-17-year-olds already safely got the shot, the only one available for children in the country.

Omicron variant: US FDA approves 1st oral pill by Pfizer to treat Covid

Omicron variant: US FDA approves 1st oral pill by Pfizer to treat Covid

Thu, Dec 23, 2021

As Omicron variant spreads globally, the US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for the Pfizer antiviral pill to treat Covid-19 along with caution for people with certain pre-existing conditions -- heralding a new era for the future, over-the-counter treatment of the deadly respiratory disease that has killed millions.

US authorises Covid-19 boosters for younger teenagers amid Omicron fears

US authorises Covid-19 boosters for younger teenagers amid Omicron fears

Fri, Dec 10, 2021

The US Centers for Disease Control and Prevention (CDC) has recommended individuals 16 and 17 years of age get a booster shot of the Pfizer-BioNTech Covid-19 vaccine at least six months after completing their first two doses.

Pfizer Covid vaccine provides partial protection against Omicron: Study

Pfizer Covid vaccine provides partial protection against Omicron: Study

Wed, Dec 08, 2021

The Pfizer COVID-19 vaccine provides less immunity against Omicron than from other coronavirus variants, according to a lab study that suggests a booster may still provide good protection.

Pfizer working on updated jab in response to Omicron variant: CEO

Pfizer working on updated jab in response to Omicron variant: CEO

Thu, Dec 02, 2021

The company is now working on an updated jab in response to the Omicron variant that could be ready in 100 days, the report added.

EU drug regulator approves first COVID shot for 5-11 years old

EU drug regulator approves first COVID shot for 5-11 years old

Thu, Nov 25, 2021

Pfizer-BioNTech`s vaccine, which has been approved for European Union use in teenagers between 12 and 17 years old since May, will be given in two doses of 10 micrograms three weeks apart as an injection in the upper arm, the European Medicines Agency (EMA) recommended.

Quarterly Report Card - Pfizer, Bata India, RattanIndia Power, Uflex announce Q2 results - know how they performed?

Quarterly Report Card - Pfizer, Bata India, RattanIndia Power, Uflex announce Q2 results - know how they performed?

Wed, Nov 03, 2021

Pfizer, Bata India, RattanIndia Power and Uflex announced earnings results for the quarter ended 30 September 2021 on Wednesday. The results were declared after market hours. Here is a sneak peek into the performance exhibited bt individual companies

Pfizer says its Covid vax 90.7% effective in kids aged 5-11

Pfizer says its Covid vax 90.7% effective in kids aged 5-11

Sat, Oct 23, 2021

Pfizer and its partner BioNTech said their Covid-19 vaccine is safe and 90.7 per cent effective against symptomatic coronavirus in children aged 5 to 11.

Pfizer, Moderna raise Covid vaccine prices in EU

Pfizer, Moderna raise Covid vaccine prices in EU

Mon, Aug 02, 2021

The supply contracts are being renewed as Europe is anxious to secure supplies for potential booster shots in the face of the spread of the highly infectious Delta variant.

COVID-19 Vaccination Latest News in India: Check the status of Moderna, Pfizer and Johnson & Johnson vaccines in India

COVID-19 Vaccination Latest News in India: Check the status of Moderna, Pfizer and Johnson & Johnson vaccines in India

Wed, May 26, 2021

Next year, Moderna is expecting to launch a single-dose COVID-19 vaccine in India and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday

ICICI Securities upgrades Divi's Laboratories, Pfizer and Jubilant Pharma to BUY

ICICI Securities upgrades Divi's Laboratories, Pfizer and Jubilant Pharma to BUY

Tue, Mar 30, 2021

ICICI Securities remain positive on the pharmaceutical sector considering high possibility of growth revival in India formulations on low base of FY21, stable pricing in US generics and sustenance of cost control initiatives seen during FY21 due to pandemic, albeit partially over long term.

Pfizer - Core brands growth to rise, valuation attractive; Anand Rathi upgrades Pfizer to a Buy with a target of Rs 5655

Pfizer - Core brands growth to rise, valuation attractive; Anand Rathi upgrades Pfizer to a Buy with a target of Rs 5655

Tue, Feb 09, 2021

On its better hospitals and vaccine performances, Pfizer’s Q3 FY21 sales grew 10.3% yoy to Rs 5.9 bn. Its gross margin expanded 149 bps yoy to 64.2%, while the EBITDA margin expanded 836 bps yoy to 33.2% on account of lower promotional costs. Lower other income and a higher tax rate reduced adjusted PAT growth to 19.8% (Rs 1.4 bn).

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x